{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-257259","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2022-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.776403+00:00","generated_at":"2026-06-23T05:37:44.409656+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vir Biotechnology awarded up to $1B BARDA contract for influenza and pandemic preparedness","bullets":["BARDA to invest ~$55M initially for VIR-2482 (influenza prophylactic mAb) development through Jan 2026.","Phase 2 trial of VIR-2482 expected to start H2 2022; initial data anticipated mid-2023.","Potential total investment up to $1B if BARDA exercises up to 12 options for additional candidates.","Contract supports development of up to 10 emerging infectious disease or medical countermeasure candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-257259","json":"https://secwatch.observer/filing/0001193125-22-257259.json","markdown":"https://secwatch.observer/filing/0001193125-22-257259.md","text":"https://secwatch.observer/filing/0001193125-22-257259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000119312522257259/0001193125-22-257259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000119312522257259/d387221d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:37:44.409656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}